Workflow
奥锐转债
icon
Search documents
奥锐特药业股份有限公司首次公开发行部分限售股上市流通公告
Core Points - The announcement details the listing of 6,606,000 restricted shares of Aorite Pharmaceutical Co., Ltd. on September 22, 2025, following the expiration of a 60-month lock-up period [2][3][12] - The total share capital of the company after the initial public offering (IPO) is 406,195,234 shares, with 1.63% of this being the newly listed restricted shares [4][6][8] Group 1: Listing Details - The type of stock being listed is the initial public offering (IPO) shares, with a total of 6,606,000 shares available for trading [2] - The listing date for the restricted shares is set for September 22, 2025 [3][13] Group 2: Share Capital Changes - The company initially issued 41,000,000 shares during its IPO, resulting in a total share capital of 401,000,000 shares, which includes 41,000,000 unrestricted shares and 360,000,000 restricted shares [4][5] - The total share capital increased to 406,195,234 shares due to the issuance of 5,195,000 restricted shares under the 2022 incentive plan and the conversion of 234 shares from convertible bonds [6][8] Group 3: Lock-up Commitments - The shareholder, Tiantai Boren Investment Management Partnership, has committed to a lock-up period of 60 months for the shares prior to the IPO and has adhered to this commitment [9][11] - The shareholder's commitment includes conditions for share reduction and penalties for non-compliance, ensuring transparency and accountability [9]
奥锐特药业股份有限公司关于部分高管减持股份计划公告
Core Viewpoint - The announcement details a share reduction plan by a senior executive of Aorite Pharmaceutical Co., Ltd. due to personal financial needs, involving a maximum reduction of 62,500 shares, which is 0.02% of the total share capital [2][3]. Group 1: Executive Shareholding Information - As of the announcement date, the total number of shares for Aorite Pharmaceutical is 406,195,234, with the executive Zhao Zhenping holding 250,000 shares, representing 0.06% of the total share capital [2]. Group 2: Reduction Plan Details - The executive plans to reduce shares through centralized bidding within three months after the announcement, starting 15 trading days later, with a maximum of 62,500 shares to be sold [3]. - The reduction will not exceed 25% of the executive's total shareholding, and any changes in share capital due to dividends or other corporate actions will adjust the reduction quantity accordingly [3]. Group 3: Other Relevant Information - The executive has no concerted actions with other shareholders and has made prior commitments regarding shareholding and reduction methods [4][6]. - The company will monitor the reduction plan and comply with relevant regulations, ensuring timely disclosure of any developments [9][17].
股市必读:奥锐特(605116)8月1日主力资金净流出571.48万元,占总成交额5.0%
Sou Hu Cai Jing· 2025-08-03 21:52
Core Viewpoint - As of August 1, 2025, Aorite (605116) closed at 23.96 yuan, down 0.58%, with a turnover rate of 1.19% and a trading volume of 47,500 hands, resulting in a transaction amount of 114 million yuan [1] Trading Information Summary - On August 1, Aorite's capital flow indicated a net outflow of 5.71 million yuan from main funds, accounting for 5.0% of the total transaction amount [2][3] - Retail investors showed a net inflow of 7.87 million yuan, representing 6.88% of the total transaction amount [2] Company Announcement Summary - Aorite Pharmaceutical Co., Ltd. announced the redemption of part of its idle raised funds for cash management, allowing the use of up to 300 million yuan of idle raised funds, with a rolling usage limit valid for 12 months from the approval date of the third board meeting [2] - On June 30, 2025, the company invested 40 million yuan in a structured deposit product from Industrial Bank, which had a term from July 1 to July 31, 2025, and has since been redeemed, yielding a profit of 62,500 yuan [2][3]
奥锐特: 奥锐特药业股份有限公司关于“奥锐转债”2025年付息公告
Zheng Quan Zhi Xing· 2025-07-21 16:13
Key Points - The company announced the interest payment schedule for its convertible bonds, "Aorite Convertible Bonds," with the interest payment date set for July 28, 2025 [1][6] - The interest accrual period for the bonds is from July 26, 2024, to July 25, 2025, with a coupon rate of 0.3% [3][5] - The bondholders will receive a total interest amount of RMB 0.3 per bond (before tax) for each bond with a face value of RMB 100 [3][5] - The tax on interest income for individual investors is set at 20%, resulting in a net payment of RMB 0.24 per bond after tax [5] - The bond's registration date for interest payment is July 25, 2025, and the ex-dividend date is July 28, 2025 [4][6] - The company has appointed China Securities Depository and Clearing Corporation Limited Shanghai Branch to handle the interest payment process [4][5]
奥锐特: 奥锐特药业股份有限公司关于“奥锐转债”2025年跟踪信用评级结果的公告
Zheng Quan Zhi Xing· 2025-06-27 16:24
Group 1 - The core viewpoint of the announcement is that the credit rating for the company's convertible bonds and the company itself remains unchanged at AA- with a stable outlook [1][2] - The previous credit rating for the convertible bonds was AA- and the company’s main credit rating was also AA- with a stable outlook [1] - The credit rating was conducted by China Chengxin International Credit Rating Co., Ltd. based on a comprehensive analysis of the company's operational status and industry conditions [2] Group 2 - The tracking credit rating report was issued on June 27, 2025, confirming that both the convertible bonds and the company maintain their AA- ratings [2] - The announcement emphasizes that there are no false records, misleading statements, or significant omissions in the content [1]
奥锐特: 奥锐特药业股份有限公司关于因实施权益分派调整“奥锐转债”转股价格的公告
Zheng Quan Zhi Xing· 2025-06-12 10:28
Core Viewpoint - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of a cash dividend distribution for the fiscal year 2024, resulting in a new conversion price of 24.94 CNY per share, effective from June 20, 2025 [1][4][5] Group 1: Bond Information - The company issued convertible bonds amounting to 812,120,000.00 CNY on July 26, 2024, with a maturity of 6 years and an initial conversion price of 25.23 CNY per share [2][3] - The conversion period for the bonds is from February 5, 2025, to July 25, 2030 [2] Group 2: Dividend Distribution - The company plans to distribute a cash dividend of 2.90 CNY per 10 shares (including tax) to all shareholders, excluding treasury stock [2][3] - The cash dividend per share is calculated to be 0.2890 CNY [5] Group 3: Conversion Price Adjustment - The conversion price adjustment formula is based on the distribution of cash dividends and is calculated as follows: P1 = P0 - D, where P0 is the original conversion price and D is the cash dividend per share [3][5] - The adjusted conversion price is calculated to be 24.94 CNY per share, down from the original price of 25.23 CNY per share [4][5] - The bonds will be suspended from conversion from June 12, 2025, to June 19, 2025, and will resume conversion on June 20, 2025 [1][4]
奥锐特: 奥锐特药业股份有限公司关于调整2024年度利润分配现金分红总额的公告
Zheng Quan Zhi Xing· 2025-06-12 10:16
Summary of Key Points Core Viewpoint - The company has announced an adjustment to the total cash dividend distribution for the fiscal year 2024, reducing it from RMB 117,796,550.00 to RMB 117,401,979.77 due to changes in the number of shares eligible for profit distribution resulting from convertible bond conversions and share buybacks [1][3]. Group 1: Dividend Distribution Adjustment - The total cash dividend amount for 2024 is adjusted to RMB 117,401,979.77 (including tax), maintaining a distribution of RMB 2.90 per 10 shares [1][3]. - The adjustment is necessary due to changes in the total number of shares participating in the profit distribution caused by the conversion of convertible bonds and the company's share buyback program [1][2]. Group 2: Convertible Bonds and Share Buyback - The company has issued convertible bonds, with a conversion period from February 5, 2025, to July 25, 2030, and an initial conversion price of RMB 25.23 per share, resulting in an increase of 234 shares due to conversions [2]. - The company has repurchased a total of 1,360,900 shares since January 1, 2025, with 79 shares used for convertible bond conversions, leaving 1,360,821 shares in the repurchase account, which will not participate in the profit distribution [2].
奥锐特: 奥锐特药业股份有限公司实施2024年度权益分派时“奥锐转债”停止转股的提示性公告
Zheng Quan Zhi Xing· 2025-06-06 08:15
Group 1 - The company will stop the conversion of its convertible bonds "Aorite Convertible Bonds" (bond code: 111021) from June 12, 2025, until the equity distribution registration date due to the 2024 annual equity distribution [1][2] - The company plans to distribute a cash dividend of 2.90 yuan (including tax) for every 10 shares to all shareholders, excluding treasury stock [1][2] - The company will adjust the conversion price of the convertible bonds according to the issuance terms and relevant regulations after the equity distribution [2] Group 2 - The company will announce the implementation of the equity distribution and the adjustment of the convertible bond conversion price on June 13, 2025 [2] - Holders of the convertible bonds can convert their bonds into shares until June 11, 2025, to enjoy the equity distribution [2] - The company will maintain the per-share distribution ratio unchanged, adjusting the total distribution amount if there are changes in the total share capital before the equity distribution registration date [1][2]
奥锐特: 奥锐特药业股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Zheng Quan Zhi Xing· 2025-06-03 08:17
Group 1 - The company announced a share repurchase plan with a total expected amount between 60 million and 120 million RMB [1][2] - The repurchase will be conducted through centralized bidding and is intended for the conversion of the company's convertible bonds [1][2] - As of May 31, 2025, the company has repurchased a total of 1.3609 million shares, representing 0.34% of the total share capital, with a total expenditure of approximately 27.09 million RMB [2] Group 2 - The repurchase price ranged from 18.83 RMB to 21.00 RMB per share [1][2] - The board of directors approved the repurchase plan with unanimous consent during the twelfth board meeting [1] - The repurchase period is set to last for up to 12 months following the board's approval [1]
4月24日投资提示:港股小盘LOF跌停
集思录· 2025-04-23 14:38
明天161124港股小盘LOF会封死跌停的,而且,后天还会封死跌停,我怀疑最后就是跌到成本附近,大家白忙活。 这让我想起个故事。 上次我去澡堂子洗澡: 牛:老板,你这儿洗澡多少钱? 老板:男浴池10元,女浴池100元。 牛:为什么女浴池那么贵? 老板:你就说想去男浴池还是女浴池? 牛:一听这话,果断交了100块。 兴冲冲进女浴池一看,全是买票进来的男的。。。 被骗过一次长记性了。 但前天我去澡堂子,心里又痒痒了,我想虽然概率很低,但成本不高,万一要是能遇到个女的呢? 最后还是忍不住买了100块钱的票。 风语转债:董事会提议下修 维尔转债:下修到底 赛力医疗:收到证监会湖北监管局行政处罚决定书 | 转债代码 | 转债名称 | 强赎天计数 | 现价 | 转股价值 | 溢价率 | 剩余规模 | 转债占正股 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | (亿元) | 流通市值比 | | 128144 | 利民转债 | 还需0天 | 145.777 | 146.35 | -0.39% | 5.042 | 11.10% | | 1136 ...